|
|
|
TKAI - Tokai Pharmaceuticals, Inc.
Tokai Pharmaceuticals, Inc. was a clinical stage biopharmaceutical company that focused on developing therapies for the treatment of prostate cancer and other hormonally-driven diseases. The company was founded in 2004 and was headquartered in Cambridge, Massachusetts.
The company's lead product candidate, galeterone, was a small molecule drug that targeted the androgen receptor and had the potential to treat both castration-resistant prostate cancer (CRPC) and other hormonally-driven diseases. Tokai Pharmaceuticals, Inc. had completed multiple clinical trials for galeterone and had received Fast Track and Orphan Drug designations from the U.S. Food and Drug Administration (FDA) for the treatment of CRPC.
In 2018, Tokai Pharmaceuticals, Inc. was acquired by Novogen Limited, an Australian biotechnology company focused on the development of oncology therapeutics. The acquisition included all of Tokai's intellectual property related to galeterone and its other product candidates.
|
|
|
|
|
